Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion; Shares Surge 66%

Key Facts

1Servier agreed to acquire Day One Biopharmaceuticals for $21.50 per share.

2The total deal is valued at approximately $2.5 billion, causing the stock to jump 66%.

3The acquisition includes the brain tumor drug Ojemda and other oncology pipeline assets.

Servier has entered into a definitive agreement to acquire Day One Biopharmaceuticals (DAWN) in an all-cash transaction valued at approximately $2.5 billion. Under the terms of the deal, Day One shareholders will receive $21.50 per share, representing a substantial premium that triggered a 66% surge in the stock price. The strategic acquisition allows Servier to significantly bolster its oncology portfolio, specifically gaining access to the FDA-approved brain tumor treatment, Ojemda. In addition to the lead drug, the deal includes various clinical-stage assets within Day One's oncology pipeline. This transaction highlights the ongoing consolidation trend within the biotechnology sector as major firms seek to integrate innovative therapies. The deal is expected to close following customary regulatory approvals and closing conditions.